Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Supreme Court Rules Against GE Drug Makers, Allows Patent Extension for Eisai’s Aricept
September 15, 2011
- JCR Revises Half-, Full-Year Business Forecasts for FY Ending March 2012
September 14, 2011
- DSP to End Sales of Melbin
September 14, 2011
- Medipal HD, JCR Announce Codevelopment Agreement for 3 Products
September 14, 2011
- FDA Advisory Committee Recommends Approval of Rivaroxaban for SPAF
September 13, 2011
- AZ, Daiichi Sankyo to Launch Nexium on Sept. 15
September 13, 2011
- Takeda Initiates PIII Trials of Antidiabetic TAK-875 in Japan
September 13, 2011
- NBI Initiates PIII Study for BIBF1122 in Japan
September 12, 2011
- TransGenic Submits Patent Application for Novel Lung Cancer Marker Antibody
September 12, 2011
- Santen to Enhance Sales Functions by Creating New Group
September 12, 2011
- Toho Pharmaceutical to Acquire Shouei in January 2012
September 12, 2011
- Astellas to Transfer Distribution Rights for Targocid, Maalox to sanofi-aventis
September 12, 2011
- Takeda Begins Domestic PII Clinical Trials for Leuplin Successor TAK-385
September 12, 2011
- Medinet Granted Patent on Cancer Antigen Peptide in 11 European Countries
September 12, 2011
- Helsinn Initiates Global PIII Program for Anamorelin
September 12, 2011
- Takara Bio to Supply Plasmid Vectors for iPS Cell Production to Kyoto University
September 12, 2011
- JAK Inhibitor May Be as Effective as Biologics at Lower Cost: Prof. Takeuchi of Keio University
September 12, 2011
- Tablet Terminals Effective for Changing Doctors’ Prescribing Behavior: M3
September 12, 2011
- MTPC Applies for DPP-4 Inhibitor Teneligliptin
September 12, 2011
- Toyama Chemical, Eisai Resubmit NDA for RA Treatment T-614
September 12, 2011
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…